dc.contributorRodríguez Lesmes, Paul Andres
dc.creatorCeballos González, Mateo
dc.date.accessioned2019-08-23T14:06:30Z
dc.date.available2019-08-23T14:06:30Z
dc.date.created2019-08-23T14:06:30Z
dc.date.issued2019
dc.identifierhttp://repository.urosario.edu.co/handle/10336/20159
dc.identifierhttps://doi.org/10.48713/10336_20159
dc.description.abstractThis paper develops an initial estimation of the health cost-effectiveness threshold in the Colombian health system, from the perspective of the supply-side. This approach defines a theoretical and empirical framework, explicit and consistent, that can be replicated in different health settings. In the supply-side approach, the threshold is defined as the opportunity cost of allocating resources to a new technology, in terms of the health benefits displaced or forgone as a consequence of their unavailability to finance other alternatives that compete for the same budget; and its estimate is based on the quantification of the causal effect of the spending on health benefits. To carry out the research, an unbalanced panel-type econometric model with three dimensions was developed: 1) the Colombians insurers Entidades Administradoras de Planes de Beneficios (EAPB); 2) different groups of health conditions, based on the International Shortlist for Hospital Morbidity Tabulation of the World Health Organization; and 3) a temporary period from 2012 to 2016. The health outcome used were the Life-Years Gained (LYG), calculated using life tables, illness adjusted life expectancy and survival curves methodologies. The expected endogeneity was tried to be resolved through an instrumental variables approach. The estimation was carried out using two-stage ordinary last squares. To run the model, a novel database was built from multiple institutional sources available in the country from the period 2012-2016: Estudios de Suficiencia, Estadísticas Vitales, Registro Individual de Prestación de Servicios, Base de Datos Única de Afiliados, and the financial information of the Superintendencia de Salud. Due to the availability of the information, the estimate was delimited to the universe of the contributory regime and the technologies included in the Plan de Beneficios con cargo a la Unidad de Pago por Capitación (PBS-UPC). As instrumental variables, we explore the use of the financial reports of the EAPB each year, and the per capita expenditure of new technologies included in the PBS-UPC between 2012 and 2016 for each EAPB, each health conditions groups, and each year. The results of the econometric model, without adjusting for the instrumental variables, calculate a coefficient between the expenditure and the LYG of 0.0933 not statistically significant, which implies a cost-effectiveness threshold of $8,772,177 per LYG. Taking into account the instrumental variable of financial reports, the estimated coefficient was 5,521 statistically significant at a 95% confidence level, and a threshold of $157,775 per LYG. On the other hand, the estimation with the instrumental variable of the per capita expenditure of new technologies included in the PBS-UPC between 2012 and 2016, did not yield logical and statistically significant results. Taking into account this scenarios, it is considered that the best initial estimation of the cost-effectiveness threshold in the Colombian health system is $8,772,177 per LYG. To our knowledge, this is the first empirical estimate of the threshold per YLG from the supply-side approach for Colombia, Latin America, and for any low-middle income country. The main limitations of this paper are detailed below. First, the estimate is limited to the universe of the contributory regime and the technologies included in the PBS-UPC, so a future research agenda, if the information sources allow it, would be the inclusion of these two universes within the proposed model, Second, other measures beside the LYG are recommended in the literature, such as the Quality-Adjusted Life Years (QALY) and the Disability-Adjusted Life Years (DALY), which could be taken into account to estimate thresholds for different health outcomes. Third, a limitation of this paper is related to the impossibility in identifying and quantifying a good instrument that corrects the expected endogeneity between spending and health benefits. Future research could modify the estimation of the threshold if an appropriate instrument with the sufficient information is found.
dc.languagespa
dc.publisherMaestría en economía de las políticas públicas
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceArango, Mónica; Arroyave, Elizabeth; Hernández, Juan (2011). “Valoración del riesgo financiero (CFAR) en las EPS a través de opciones reales: una aplicación al nivel de atención IV”. Revista Ingenierías Universidad de Medellín, Vol. 10, No. 19, pp: 125-136.
dc.sourceAriste, Ruolz; Di Matteo, Livio (2017). “Value for money: an evaluation of health spending in Canada”. International Journal of Health Economics and Management, Vol. 17, No. 3, pp: 289-310.
dc.sourceAtehortúa, Sara; Ceballos, Mateo; Gaviria, Carlos Felipe; Mejía, Aurelio (2013). “Evaluación de la calidad metodológica de la literatura en evaluación económica en salud en Colombia: una revisión sistemática”, Biomédica, Vol. 33, No. 4, pp: 615-630.
dc.sourceBirch, Stephen; Gafni, Amiram (1992). “Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?” Journal of Health Economics, Vol. 11, No. 3, pp: 279-296.
dc.sourceBlack, William (1990). “The CE plane. A graphical presentation of cost-effectiveness”. Medical Decision Making, Vol. 10, No. 3, pp: 212-214.
dc.sourceBobinac, Ana; van Exel, N.J.A; Rutten, Franz; Brouwer, Werner (2010). “Willingness to pay for a quality-adjusted life-year: the individual perspective”. Value in Health, Vol. 13, No. 8, pp: 1046-1055.
dc.sourceCaro, Jaime; Möller, Jorgen (2014). “Decision-Analytic Models: Current Methodological Challenges”. Pharmacoeconomics, Vol. 32, No. 10, pp: 943-950.
dc.sourceCastro-Iragorri (2015). “La administración cuantitativa del riesgo financiero en la provisión de un plan de salud”. Revista Gerencia y Políticas de Salud, Vol. 14, No. 28, pp: 51-62.
dc.sourceClaxton, Karl; Martin, Steve; Soares, Marta; Rice, Nigel; Spackman, Eldon; Hinde, Sebastian; Devlin, Nancy; Smith, Peter, Sculpher, Mark (2015). “Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold”. Health Technology Assessment, Vol. 19, No. 14, pp: 1-503.
dc.sourceCleemput, Irina; Neyt, Mmattias; Thiry, Nancy; De Laet, Chris; Leys, Mark (2011). “Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions”. International Journal of Technology Assessment in Health Care, Vol. 27, No. 1, pp: 71-76.
dc.sourceComisión Económica para América Latina y el Caribe (2017). Observatorio Demográfico de América Latina: Tablas de Mortalidad, Primera Edición, Santiago de Chile, Naciones Unidas.
dc.sourceCulyer, Anthony (2016). “Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use”. Health Economics, Policy and Law, Vol. 11, No. 4, pp: 415-432.
dc.sourceDrummond, Michael; Sculpher, Mark; Claxton, Karl; Stoddart, Greg; Torrance, George (2015). Methods for the Economic Evaluation of Health Care Programmes, Cuarta Edición, New York, Oxford University Press.
dc.sourceEdney, Laura Catherine; Haji Ali Afzali, Hossein; Chai Cheng, Terence; Karnon, Jonathan (2018). “Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System”, Pharmacoeconomics, Vol. 36, No. 2, pp: 239-252.
dc.sourceFuchs, Victor (2001). “El futuro de la economía de la salud”. Lecturas de Economía, Vol. 55, pp. 9-30.
dc.sourceGafni, Amiram; Birch, Stephen (2006). “Incremental cost-effectiveness ratios (ICERs): the silence of the lambda”. Social Science & Medicine, Vol. 62, No. 9, pp: 2091-2100.
dc.sourceGlobal Burden of Disease (2018). “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017”. The Lancet, Vol. 392, No. 10159, pp: 1789-1858.
dc.sourceGravelle, Hugh; Beckhouse, Martin (1987). “International cross-section analysis of the determination of mortality”. Social Science & Medicine, Vol. 25, No. 5, pp: 427-441.
dc.sourceGray, Alistair; Clarke, Philip; Wolstenholme, Jane; Wordsworth, Sarah (2011). Applied Methods of Cost-effectiveness Analysis in Health Care. Primera Edición, New York, Oxford University Press.
dc.sourceGriffiths, Ulla Kou; Legood, Rosa; Pitt, Catherine (2016). “Comparison of Economic Evaluation Methods Across Low-income, Middle-income and High-income Countries: What are the Differences and Why?” Health Economics, Vol. 25, Supl. 1, pp: 29-41.
dc.sourceGrupo de Economía de la Salud (2015a). “Transición en el sistema de salud colombiano”. Observatorio de la Seguridad Social en Salud, No. 30, pp: 1-24.
dc.sourceGrupo de Economía de la Salud (2015b). “El gasto y la prioridad de la salud en Colombia”. Observatorio de la Seguridad Social en Salud, No. 31, pp: 1-16.
dc.sourceGuerrero, Ramíro; Guevara, César y Parody, Elizabeth (2014). Guía metodológica para la realización de evaluaciones económicas en el marco de Guías de Práctica Clínica. Grupo de Investigación PROESA, Ministerio de Salud y Protección Social, Colombia, Bogotá D.C.
dc.sourceFontalvo, Tomás; Mendoza, Adel; Visbal, Delimiro (2015). “Medición de la eficiencia financiera de las entidades promotoras de salud (eps) del régimen contributivo mediante el análisis envolvente de datos (aed)”. Universidad & Empresa, Vol. 17, No. 29, pp: 93-110.
dc.sourceHusereau, Don; Drummond, Michael; Petrou, Stavros; Carswell, Chris; Moher, David; Greenberg, Dan; Augustovski, Federico; Briggs, Andrew; Mauskopf, Josephine; Loder, Elizabeth (2013). “Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force”. Value In Health, Vol. 106, No. 2, pp: 229-242.
dc.sourceInstituto de Evaluación Tecnológica en Salud (2014). Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológica en Salud. IETS, Colombia, Bogotá D.C.
dc.sourceJohannesson, Magnus; Weinstein, Milton (1993). “On the Decision Rules of Cost-Effectiveness Analysis”. Journal of Health Economics, Vol. 12, No. 4, pp: 459-467.
dc.sourceKarlsson, Goran; Johannesson, Magnus (1996). “The decision rules of cost-effectiveness analysis”. Pharmacoeconomics, Vol. 9, No. 2, pp: 113-120.
dc.sourceMartin, Stephen; Rice, Nigel; Smith, Peter (2012). “Comparing costs and outcomes across programmes in health care”. Health Economics, Vol. 21, No. 3, pp: 316-337.
dc.sourceMejía, Aurelio; Moreno, Mabel (2014). “Evaluación económica para la toma de decisiones en salud en Colombia”. Monitor Estratégico, Vol. 5, pp: 70-75.
dc.sourceMinisterio de Salud y Protección Social (2017). Boletín del Aseguramiento en Salud. Boletín No. 1, Primer trimestre de 2017. Dirección de Regulación de la Operación del Aseguramiento en Salud, Riesgo Laborales y Pensiones. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/boletin-aseguramiento-i- trimestre-2017.pdf [Consultado en junio de 2019].
dc.sourceNixon, John; Ulmann, Philippe (2006). “The relationship between health care expenditure and health outcomes”. The European Journal of Health Economics, Vol. 7, No. 1, pp: 7-18.
dc.sourceNúñez, Jairo; Zapata, Juan Gonzalo; Castañeda, Carlos; Fonseca, Sandra Milena; Ramírez, Jaime (2012). La sostenibilidad financiera del sistema de salud colombiano-dinámica del gasto y principales retos de cara al futuro, Primera Edición, Publicaciones Fedesarrollo, Bogotá D.C., Colombia.
dc.sourceOchalek, Jessica; Lomas, James; Claxton Karl (2015). “Cost Per DALY Averted Thresholds for Low- and Middle-Income Countries: Evidence From Cross Country Data”, CHE Research Paper, Vol. 122, pp: 1-50.
dc.sourceOchalek, Jessica; Lomas, James; Claxton Karl (2018). “Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data”, BMJ Global Health, Vol. 3, No. 6, pp: e000964.
dc.sourceOrganización Mundial de la Salud (2001). Macroeconomics and Health: Investing in health for economic development. Reporte de la Comisión de Macroeconomía y Salud. Geneva: World Health Organization.
dc.sourceOrganización Mundial de la Salud (2015). Using health technology assessment for universal health coverage and reimbursement systems. Geneva, Switzerland. Disponible en: http://www.who.int/health-technology-assessment/HTA_November_meeting_report_Final.pdf [Consultado en junio de 2019].
dc.sourcePaulden, Mike; O'Mahony, James; McCabe, Christopher (2016). “Determinants of Change in the Cost-Effectiveness Threshold”. Medical Decision Making, Vol. 37, No. 2, pp: 264-276.
dc.sourcePichón-Riviere, Andrés; Augustovski, Federico; García-Marti, Sebastián (2016). “Derivation of cost-effectiveness thresholds based on per capita health expenditures and life expectancy, and country-level estimates for 194 countries”, IECS Technical Document, No 16. Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
dc.sourcePichón-Riviere, Andrés; Augustovski, Federico; García-Marti, Sebastián (2017). “The Efficiency Path To Universal Health Coverage: Derivation Of Cost-Effectiveness Thresholds Based On Health Expenditures And Life Expectancy. Updated Country-Level Estimates For 194 Countries”. Value In Health, Vol. 20, No. 9, pp: A858.
dc.sourcePitt, Catherine; Goodman, Catherine; Hanson, Kara (2016). “Economic Evaluation In Global Perspective: A Bibliometric Analysis Of The Recent Literature”, Health Economics, Vol. 25, Supl. 1, pp: 9-28.
dc.sourceRevill, Paul; Sculpher, Mark (2012). “Cost effectiveness of interventions to tackle non-communicable diseases”, British Medical Journal, Editorials, pp: e609.
dc.sourceRyen, Linda; Svensson, Mikael (2015). “The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature”, Health Economics, Vol. 24, No. 10, pp: 1289-1301.
dc.sourceShillcut, Samuel; Walker, Damian; Goodman, Catherine; Mills, Anne (2009). “Cost-Effectiveness in Low- and Middle-Income Countries: A Review of the Debates Surrounding Decision Rules”, Pharmacoeconomics, Vol. 27, No. 11, pp: 903-917.
dc.sourceSiverskog, Jonathan; Henriksson, Martin (2019). “Estimating the marginal cost of a life year in Sweden's public healthcare sector”, The European Journal of Health Economics, Vol. 20, No. 5, pp: 751-762.
dc.sourceUniversidad de Tufts (2018). Cost-Effectiveness Analysis (CEA) Registry. Tufts Medical Center. Disponible en: https://cevr.tuftsmedicalcenter.org/databases/cea-registry [Consultado en junio de 2019]
dc.sourceVallejo-Torres, Laura; García-Lorenzo, Borja; Castilla, Iván; Valcárcel-Nazco, Cristina; García-Pérez, Lidia; Linertová, Renata; Polentinos-Castro, Elena; Serrano-Aguilar, Pedro (2016). “On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?” Value In Health, Vol. 19, No. 5, pp: 558-566.
dc.sourceVallejo-Torres, Laura; García-Lorenzo, Borja; Serrano-Aguilar, Pedro (2018). “Estimating a cost-effectiveness threshold for the Spanish NHS” Health Economics, Vol. 27, No. 4, pp: 746-761.
dc.sourceWagstaff, Adam; Culyer, Anthony (2012). “Four decades of health economics through a bibliometric lens”. Journal of Health Economics, Vol. 31, No. 2, pp: 406-439.
dc.sourceWeinstein, Milton; Zeckhauser, Richard (1973). “Critical ratios and efficient allocation”, Journal of Public Economics, Vol. 2, No. 2, pp: 147-157.
dc.sourceWoods, Beth; Revill, Paul; Sculpher, Mark; Claxton, Karl (2015). “Country-level cost-effectiveness thresholds: initial estimates and the need for further research” CHE Research Papers, Vol. 109, pp: 1-24.
dc.sourceWoods, Beth; Revill, Paul; Sculpher, Mark; Claxton, Karl (2016). “Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research” Value in Health, Vol. 19, No. 8, pp: 929-935.
dc.sourceXie, Feng; Gaebel, Kathryn; Perampaladas, Kuhan; Doble, Brett; Pullenayegum, Eleanor (2013). “Comparing EQ-5D Valuation Studies: A Systematic Review and Methodological Reporting Checklist”. Medical Decision Making, Vol. 34, No. 1, pp: 8-20.
dc.sourceZerda, Álvaro (2014). “Evaluación económica de tecnologías en salud: retos y perspectivas”, Biomédica, Vol. 34, No. 2, pp: 161-163.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectEconomía de la Salud
dc.subjectEvaluación Económica
dc.subjectUmbral de Costo-Efectividad
dc.subjectRelación entre el Gasto y los Beneficios en Salud
dc.subjectEficiencia
dc.titleEstimación del umbral de costo-efectividad en salud por año de vida ganado para Colombia
dc.typemasterThesis


Este ítem pertenece a la siguiente institución